Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,628 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: gemcitabine Clear all
Terminated Phase 2 Interventional Results available

Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin

NCT02030574
View directory record Official record
Conditions
Invasive Bladder Cancer, Bladder Cancer
Interventions
Gemcitabine and fractionated cisplatin (combination treatment)
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 26, 2026, 4:43 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer

NCT00267020
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
enzastaurin, gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 26, 2026, 4:43 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

NCT00003727
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, recombinant interferon alfa, sargramostim, therapeutic autologous lymphocytes, carmustine, cyclophosphamide, etoposide, gemcitabine hydrochloride, melphalan, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Up to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 26, 2026, 4:43 AM EDT
Not listed Phase 3 Interventional

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

NCT00005871
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
San Ramon, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 26, 2026, 4:43 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT06929286
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer
Interventions
Nadofaragene Firadenovec, Gemcitabine, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Baltimore, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 26, 2026, 4:43 AM EDT
Terminated Phase 1 Interventional

A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin

NCT01641575
View directory record Official record
Conditions
Solid Tumor, Non-small-cell Lung Cancer, Lung Cancer
Interventions
CO-1.01 and Cisplatin
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 26, 2026, 4:43 AM EDT
Withdrawn Phase 2 Interventional

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

NCT02850874
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Adenocarcinoma
Interventions
Hyperthermic intraperitoneal chemotherapy, Open pancreaticoduodenectomy, Gemcitabine
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 26, 2026, 4:43 AM EDT
Recruiting Phase 1 Interventional

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

NCT07107750
View directory record Official record
Conditions
Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Interventions
Emavusertib, Gemcitabine, Cisplatin, Durvalumab
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 26, 2026, 4:43 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

NCT01443078
View directory record Official record
Conditions
Lung Cancer
Interventions
pemetrexed, cisplatin, Carboplatin, Gemcitabine Hydrochloride, Vinorelbine Tartrate, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 26, 2026, 4:43 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

NCT02301143
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Gemcitabine, Chemoradiation, Capecitabine, Surgery
Drug · Procedure
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 26, 2026, 4:43 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers

NCT07769502
View directory record Official record
Conditions
Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
Interventions
Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hattiesburg, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 4:43 AM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers

NCT00832637
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer, Periampullary Adenocarcinoma, Gallbladder Cancer, Extrahepatic Bile Duct Cancer
Interventions
Cisplatin, Erlotinib, Gemcitabine
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
San Francisco, California • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 26, 2026, 4:43 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

NCT00179751
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
CC-5013, gemcitabine
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Metairie, Louisiana • St Louis, Missouri • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2005 · Synced Oct 26, 2026, 4:43 AM EDT
Completed Phase 3 Interventional

Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy

NCT00006453
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, gemcitabine hydrochloride
Drug
Lead sponsor
AGO Study Group
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 26, 2026, 4:43 AM EDT
Terminated Phase 1 Interventional

Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer

NCT00878657
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 26, 2026, 4:43 AM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

NCT00583622
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Bevacizumab, Carboplatin, Docetaxel, Gemcitabine, Melphalan, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 26, 2026, 4:43 AM EDT
Completed Phase 1 Interventional

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

NCT02309177
View directory record Official record
Conditions
Breast Neoplasms, Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Nivolumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 26, 2026, 4:43 AM EDT
Active, not recruiting Phase 2 Interventional

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

NCT04594772
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Folfirinox, Gemcitabine, radiation therapy, Pancreatectomy
Drug · Radiation · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Tucson, Arizona • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 26, 2026, 4:43 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients

NCT00907166
View directory record Official record
Conditions
Cancer, Pancreatic Cancer, Pancreatic Carcinoma
Interventions
CPI-613, Gemcitabine
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
The Bronx, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 26, 2026, 4:43 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer

NCT03848182
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, TT vaccine booster
Drug · Biological
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 26, 2026, 4:43 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

NCT01945775
View directory record Official record
Conditions
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions
talazoparib, Physician's-Choice
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
207
States / cities
Flagstaff, Arizona • Scottsdale, Arizona • Antioch, California + 136 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 26, 2026, 4:43 AM EDT
Recruiting Phase 1 Interventional

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

NCT03093909
View directory record Official record
Conditions
Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasm of Male Genital Organs, Malignant Neoplasms of Mesothelial and Soft Tissue, Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Malignant Neoplasms of Thyroid and Other Endocrine Glands, Malignant Neoplasms of Urinary Tract, Melanoma and Other Malignant Neoplasms of Skin
Interventions
Gemcitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 26, 2026, 4:43 AM EDT
Completed Phase 2 Interventional Results available

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

NCT00282087
View directory record Official record
Conditions
Leiomyosarcoma, Uterine Neoplasm
Interventions
gemcitabine, docetaxel, doxorubicin
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Oct 26, 2026, 4:43 AM EDT
Recruiting Phase 2 Interventional

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

NCT04891289
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Gemcitabine, Oxaliplatin, Dexamethasone, Floxuridine (FUDR), Implanted Medical Device
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Bethesda, Maryland • St Louis, Missouri • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 26, 2026, 4:43 AM EDT